Skip to content
2000
  • ISSN: 1568-0061
  • E-ISSN: 1568-0061

Abstract

Endothelial dysfunction is a feature of a variety of clinical states of insulin resistance,and increasingly it is recognized that pre-diabetic states of insulin resistance are associated not only with insulin resistance but with increased cardiovascular risk.The metabolic syndrome which typically accompanies insulin resistance brings aberrations in a number of classical cardiovascular risk factors,but it appears that insulin resistance itself represents an additional,non-classical risk factor.Therefore,the approach to treating the endothelium in patients with the metabolic syndrome might include therapies targeting insulin resistance. In this review,we provide a detailed overview of the current state of knowledge regarding the biguanide metformin and its effects on the endothelium.Its mode of action is reviewed,along with the available data from laboratory and experimental studies related to vascular function in animals and in humans.Metformin has beneficial effects on endothelial function which appear to be mediated through its effects to improve insulin resistance.Therapeutically targeting insulin resistance appears to be a viable route to improving endothelial function in clinical states of insulin resistance.

Loading

Article metrics loading...

/content/journals/cdtchd/10.2174/1568006043481275
2004-03-01
2025-09-01
Loading full text...

Full text loading...

/content/journals/cdtchd/10.2174/1568006043481275
Loading

  • Article Type:
    Review Article
Keyword(s): endothelin; endothelium; insulin; insulin resistance; metabolic syndrome; metformin
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test